Thomas Meek
professor
Biochemistry and Biophysics
Texas A and M University
United States of America
Biography
Marketed drugs have been developed for representatives of all six classes of enzymes, and comprise essential therapies for the treatment of cancers, HIV/AIDS, hypercholesterolemia, and bacterial infections. The availability of known point mutations that are causative of human cancers , as well as the full genomic descriptions of many pathogens, such as parasitic protozoa and infectious bacteria, provides an emerging means to identify new or known enzymes that would constitute potential drug targets
Research Interest
We will design and synthesize candidate inhibitors, and test them against these and other enzyme targets, and determine their suitability as potential drug candidates.
Publications
-
Brandt, M, Szewczuk, LM, Zhang, H, Hong, X, McCormick, PM, Lewis, TS et al.. Development of a high-throughput screen to detect inhibitors of TRPS1 sumoylation. Assay Drug Dev Technol. 2013;11 (5):308-25. doi: 10.1089/adt.2012.501. PubMed PMID:23772552
-
Poulin, MB, Schneck, JL, Matico, RE, McDevitt, PJ, Huddleston, MJ, Hou, W et al.. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36. Proc. Natl. Acad. Sci. U.S.A. 2016;113 (5):1197-201. doi: 10.1073/pnas.1521036113. PubMed PMID:26787850. PubMed Central PMC4747696
-
Pham, TV, Murkin, AS, Moynihan, MM, Harris, L, Tyler, PC, Shetty, N et al.. Mechanism-based inactivator of isocitrate lyases 1 and 2 from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2017;114 (29):7617-7622. doi: 10.1073/pnas.1706134114. PubMed PMID:28679637. PubMed Central PMC5530696
